CA2414374C - Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof - Google Patents

Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof Download PDF

Info

Publication number
CA2414374C
CA2414374C CA2414374A CA2414374A CA2414374C CA 2414374 C CA2414374 C CA 2414374C CA 2414374 A CA2414374 A CA 2414374A CA 2414374 A CA2414374 A CA 2414374A CA 2414374 C CA2414374 C CA 2414374C
Authority
CA
Canada
Prior art keywords
seq
sequence
cell
sequences
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2414374A
Other languages
English (en)
French (fr)
Other versions
CA2414374A1 (en
Inventor
Jan Zur Megede
Susan W. Barnett
Susan Engelbrecht
Estrelita Janse Van Rensburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Stellenbosch University
Original Assignee
Novartis Vaccines and Diagnostics Inc
Stellenbosch University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc, Stellenbosch University filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CA2414374A1 publication Critical patent/CA2414374A1/en
Application granted granted Critical
Publication of CA2414374C publication Critical patent/CA2414374C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2414374A 2000-07-05 2001-07-05 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof Expired - Fee Related CA2414374C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/610,313 2000-07-05
US09/610,313 US7935805B1 (en) 1998-12-31 2000-07-05 Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
PCT/US2001/021241 WO2002004493A2 (en) 2000-07-05 2001-07-05 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
CA2414374A1 CA2414374A1 (en) 2002-01-17
CA2414374C true CA2414374C (en) 2014-01-21

Family

ID=24444529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2414374A Expired - Fee Related CA2414374C (en) 2000-07-05 2001-07-05 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Country Status (10)

Country Link
US (4) US7935805B1 (enExample)
EP (3) EP2281832A3 (enExample)
JP (2) JP2004502445A (enExample)
AT (1) ATE478955T1 (enExample)
AU (1) AU2001273179A1 (enExample)
CA (1) CA2414374C (enExample)
DE (1) DE60142922D1 (enExample)
ES (1) ES2553575T3 (enExample)
WO (1) WO2002004493A2 (enExample)
ZA (2) ZA200403143B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
DK1301637T3 (da) 2000-07-14 2008-09-29 Univ Pennsylvania DNA-vacciner, der koder for HIV accessoriske proteiner
US20030138453A1 (en) * 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
EP1409694A4 (en) 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
CN1606625A (zh) 2001-10-31 2005-04-13 南非医学研究会 Hiv－1亚型分离株调节/附加基因及其修饰物和衍生物
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
CN1325512C (zh) 2002-05-16 2007-07-11 巴法里安诺迪克有限公司 Hiv调节/辅助蛋白的融合蛋白
WO2004032860A2 (en) 2002-10-07 2004-04-22 Chiron Corporation Hiv vaccine formulations
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
EP1628680B1 (en) * 2003-05-15 2012-10-24 Novartis Vaccines and Diagnostics, Inc. Hiv polynucleotides and polypeptides derived from botswana mj4
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
ES2759991T3 (es) * 2004-09-30 2020-05-12 Gen Probe Inc Ensayo para detectar y cuantificar el VIH-1
AU2011253599B2 (en) * 2004-09-30 2013-12-12 Gen-Probe Incorporated Assay for detecting and quantifying HIV-1
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
DK2947149T3 (en) 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
MX2014005548A (es) 2011-11-14 2014-08-21 Novartis Ag Complejos inmunogenicos de carbomeros polianionicos y polipeptidos env y metodos de manufactura y usos de los mismos.
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
GB201716181D0 (en) * 2017-10-04 2017-11-15 Univ Cape Town Recombinant mva with modified hiv-1 env
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US604763A (en) * 1898-05-31 Brooch
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0165942A1 (en) 1983-12-23 1986-01-02 Monash University PRODUCTION OF HUMAN INTERFERON-$g(a)
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US6610476B1 (en) * 1984-08-22 2003-08-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of HIV-1 DNA
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
WO1986003224A1 (en) 1984-11-29 1986-06-05 Scripps Clinic And Research Foundation Polypeptides and antibodies related to deglycosylated viral glycoproteins
ATE138100T1 (de) 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NZ215867A (en) 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
EP0245362B1 (en) 1985-10-24 1994-06-29 Ronald C. Kennedy Synthetic peptides and use for diagnosis and vaccination for aids and arc
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
EP0242216A1 (en) 1986-04-16 1987-10-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4879227A (en) 1986-05-06 1989-11-07 Genetics Institute, Inc. Production of a recombinant human colony stimulating factor
AU7786387A (en) 1986-07-21 1988-02-10 Southwest Foundation For Biomedical Research Composition of matter and method of immunizing against viral causative agents of aids and arc
US5135855A (en) 1986-09-03 1992-08-04 The United States Of America As Represented By The Department Of Health And Human Services Rapid, versatile and simple system for expressing genes in eukaryotic cells
US4861707A (en) 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
IL86832A (en) 1987-06-22 2002-09-12 Medeva Holdings Bv A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
WO1989002277A2 (en) 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0347435A4 (en) 1987-09-04 1991-11-21 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
US5879907A (en) 1987-09-14 1999-03-09 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof and method
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
CN1038306A (zh) 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1340748C (en) 1988-07-13 1999-09-14 Stephen Oroszlan Synthetic hiv protease gene and method for its expression
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
WO1990002568A1 (en) 1988-09-13 1990-03-22 Chiron Corporation Hiv-1 envelope muteins lacking hypervariable domains
WO1990003984A1 (en) 1988-10-03 1990-04-19 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
CA2003383A1 (en) 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
CA2004261A1 (en) 1988-12-01 1990-06-01 Charles T. Tackney Synthetic interleukin-6
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
AU5184190A (en) * 1989-02-23 1990-09-26 University Of Ottawa Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5130247A (en) 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
DE69019291T2 (de) 1989-10-23 1995-09-21 F. Hoffmann-La Roche Ag, Basel Synthetische HTLV-I Hüll-Peptide.
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5876724A (en) 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
ATE183235T1 (de) 1990-03-21 1999-08-15 Wolf Hans Joachim Prof Dr Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
WO1992001800A1 (en) 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100090A (pt) 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
JPH06508821A (ja) 1991-03-07 1994-10-06 セラジュン　インク ウイルス病治療のための細胞表面受容体を標的とする分子の使用
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5558865A (en) 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
DK0608261T3 (da) 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5174666A (en) * 1992-02-12 1992-12-29 Smith Corona Corporation Printing device having printwheel coupling means
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
DE69319120T2 (de) 1992-07-27 1999-01-07 New York University, New York, N.Y. Magnetstruktur mit hoher feldstärke
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
CA2105629A1 (en) 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US5686078A (en) 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6140059A (en) 1993-01-16 2000-10-31 Schawaller; Manfred Methods for the obtention of human immunodeficiency virsus Type 1 envelope glycoproteins in native and oligomeric form employing recombinant chimeric antigens containing collagenase recognition sites.
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JP4108118B2 (ja) 1993-03-26 2008-06-25 ジェン−プローブ・インコーポレイテッド ヒト・免疫不全ウイルス１型の検出
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US5591601A (en) 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
WO1994028929A1 (en) 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
AU693098B2 (en) 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
CA2125344A1 (en) * 1993-07-01 1995-01-02 Casey D. Morrow Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5955342A (en) 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5550280A (en) 1994-11-30 1996-08-27 Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee Hindered aromatic ester compounds useful as anti-viral agents
ES2176360T3 (es) 1994-12-30 2002-12-01 Chiron Corp Combinacion de vehiculos de administracion de genes.
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6060587A (en) 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
US6087486A (en) 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
US5649652A (en) * 1996-02-16 1997-07-22 Sackett; Eleanor L. Clothes hanger with storage hook
ATE309366T1 (de) 1996-02-22 2005-11-15 Merck & Co Inc Synthetische hiv-gene
ES2301178T3 (es) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5951975A (en) 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
CA2265889A1 (en) 1996-09-06 1998-03-12 The Regents Of The University Of California E25a protein, methods for production and use thereof
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6139833A (en) 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
FR2756843B1 (fr) * 1996-12-09 1999-01-22 Inst Nat Sante Rech Med Souches de vih-1 non-m non-o, fragments et applications
US5830697A (en) * 1997-01-21 1998-11-03 The Board Of Trustees Of The Leland Stanford Junior University P-glycoprotein mutant resistant to cyclosporin modulation
EE9900343A (et) * 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5858675A (en) 1997-05-13 1999-01-12 Incyte Pharmaceuticals, Inc. Double-stranded RNA-binding protein
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
US5932442A (en) 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6228128B1 (en) * 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
WO1999053046A2 (en) 1998-04-14 1999-10-21 Chiron Corporation Noncloning technique for expressing a gene of interest
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
US6489542B1 (en) * 1998-11-04 2002-12-03 Monsanto Technology Llc Methods for transforming plants to express Cry2Ab δ-endotoxins targeted to the plastids
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6280989B1 (en) 1999-06-17 2001-08-28 Dmitri Kapitonov Sialyltransferases
EP1228237A1 (en) 1999-11-01 2002-08-07 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
CA2402440A1 (en) * 2000-02-18 2001-08-23 University Of Washington Aids ancestral viruses and vaccines
US20030138453A1 (en) 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US7800921B2 (en) 2007-01-08 2010-09-21 Continental Automotive Systems Us, Inc. DC/DC converter
CN102847538B (zh) 2007-07-06 2016-07-06 M技术株式会社 由球碳形成的结晶的制造方法及制造装置
EP2510962A1 (en) 2011-04-12 2012-10-17 F. Hoffmann-La Roche AG Infusion pump device with re-filling scheme for cylinder-piston dosing unit

Also Published As

Publication number Publication date
EP2311958A2 (en) 2011-04-20
US20030223961A1 (en) 2003-12-04
ZA200300839B (en) 2004-07-30
US7618642B2 (en) 2009-11-17
JP2012147792A (ja) 2012-08-09
EP2281832A3 (en) 2011-12-14
ZA200403143B (en) 2005-04-26
US20100316698A1 (en) 2010-12-16
ES2553575T3 (es) 2015-12-10
AU2001273179A1 (en) 2002-01-21
WO2002004493A2 (en) 2002-01-17
EP1339738B1 (en) 2010-08-25
DE60142922D1 (de) 2010-10-07
ATE478955T1 (de) 2010-09-15
US20110212164A1 (en) 2011-09-01
CA2414374A1 (en) 2002-01-17
EP2281832A2 (en) 2011-02-09
JP2004502445A (ja) 2004-01-29
EP2311958A3 (en) 2011-08-10
EP2311958B1 (en) 2015-08-19
WO2002004493A3 (en) 2003-06-26
EP1339738A2 (en) 2003-09-03
US7935805B1 (en) 2011-05-03

Similar Documents

Publication Publication Date Title
US7943375B2 (en) Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US8133494B2 (en) Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2
EP1339738B1 (en) Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US8263394B2 (en) Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides, and uses thereof
US20080095833A1 (en) Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides, and uses thereof
EP2292772A1 (en) HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
EP1535995A1 (en) Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
CA2785699A1 (en) Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
HK1156662A (en) Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150706